StephenMAnsellMDPhD

Hematology • Rochester, MN

Hematologic Oncology

Professor of Medicine, Mayo Medical School

Join to view full profile

Dr. Ansell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ansell's full profile

Already have an account?

Office
200 1st St Sw
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1996 - 1999
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1994 - 1996
University of Pretoria Faculty of MedicineClass of 1986

Certifications & Licensure

AZ State Medical License 1998 - 2025
MN State Medical License 1996 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1999 Oct 01
Completed
Phase 1
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2001 Oct 01
Completed
Phase 2
CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma Start of enrollment: 2002 Apr 01
Completed
Phase 2
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 2
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2004 Oct 01
Completed
Phase 1, Phase 2
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2008 Apr 01
Completed
Phase 2
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia Start of enrollment: 2011 Jan 01
Completed
Phase 1, Phase 2
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Start of enrollment: 2011 Oct 01
Completed
Phase 1
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma Start of enrollment: 2012 Apr 01
Completed
Not Applicable
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 01
Terminated
Phase 2
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2014 Mar 07
Suspended
Phase 1, Phase 2
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) Start of enrollment: 2014 Mar 05
Completed
Phase 2
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) Start of enrollment: 2014 Mar 26
Completed
Phase 2
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Start of enrollment: 2015 Sep 28
Completed
Phase 1, Phase 2
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Start of enrollment: 2016 May 01
Completed
Phase 1
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Start of enrollment: 2016 May 13
Active, not recruiting
Phase 2
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Start of enrollment: 2018 Dec 21
Active, not recruiting
Phase 2
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Start of enrollment: 2017 May 17
Terminated
Phase 2
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Start of enrollment: 2020 May 29
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

2662 citations
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott
The New England Journal of Medicine. 2015-01-21
68 citations
Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines
Neha Mehta-Shah, Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Jeffrey A. Barnes
Journal of the National Comprehensive Cancer Network. 2020-05-01
171 citations
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas
George Vasmatzis, Sarah H. Johnson, Ryan A. Knudson, Rhett P. Ketterling, Esteban Braggio
Blood. 2012-09-13

Journal Articles

Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia
Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia Cells
Richard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology

Abstracts/Posters

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Stephen M Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
MLL1 Modulates IgM and Inflammatory Cytokines in Waldenstrom's Macroglobulinemia
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways
Stephen M. Ansell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Bridging the Translational Divide: The Role of the PhD
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Friday Scientific Workshop on Tumor Immune Interactions in Lymphoid Malignancies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib for the Treatment of Bing-Neel Syndrome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Tigit Expression Defines a Subset of Activated Treg Cells with Prognostic Relevance in Follicular Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Tumor Immune Interactions in Lymphoid Malignancies
60th American Society of Hematology Annual Meeting - 11/30/2018
Clinical Hematology and Oncology 2013: The 10th Annual Mayo Board Review
Mayo School of Continuous Professional Development, Scottsdale, Arizona - 1/18/2013
9th Annual Mayo Clinic Hematology Review
Mayo School of Continuous Professional Development, Minneapolis, Minnesota - 1/28/2012
Join now to see all

Press Mentions

Practice Changing: Ibrutinib in Front-line MCLDecember 11th, 2022
Cancer Death Rates Continue to Fall, Researchers ReportSeptember 22nd, 2022
ECHELON-1 Trial: Brentuximab Vedotin with Chemotherapy Offers Survival Benefit in Stage III or IV Hodgkin LymphomaJuly 26th, 2022
Join now to see all

Grant Support

P4 - Regulatory T-Cells In The Tumor Microenvironment Of B-Cell Non-HodgkinNational Cancer Institute2010–2011
Biologic Therapy For B-Cell Non-Hodgkin'S LymphomaNational Cancer Institute2008–2011
Regulatory T-Cells In The Tumor Microenvironment Of B-Cell Non-HodgkinNational Cancer Institute2007–2009
Blys Inhibition Using Taci-Fc In Patients With B-Bell Non-Hodgkins'LymphomaNational Cancer Institute2007–2008
Intra-Tumoral Injection Of Measles Virus Vaccine In Patients With Relapsed B-CelNational Center For Research Resources2005
Biologic Therapy For Beta-Cell Non-Hodgkin'S LymphomaNational Cancer Institute2004–2005
Biologic Therapy For Beta-Cell Non-Hodgkin'S LymphomaNational Cancer Institute2002–2003